{"product_id":"skye-five-forces","title":"(SKYE) Skye Bioscience, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Skye Bioscience, Inc. Porter's Five Forces Analysis helps you understand the company’s competitive environment, including rivalry, supplier power, buyer power, substitutes, and new entrants. The page already shows a real preview of the analysis, so you can review the content before buying. Purchase the full version for the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized CRO and CMO dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience is a pre-revenue biotech, so it leans on CROs and CMOs for preclinical studies, clinical trial work, and GMP drug supply. That raises supplier power because only a small pool of vendors can meet FDA-grade quality, audit, and manufacturing rules. In a low-scale model, those qualified partners can charge more, especially when timelines are tight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited source base for novel materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience’s supplier power is elevated because cannabinoid inputs, formulation know-how, and ophthalmic development materials are specialized and can come from only a few compliant vendors. That leverage matters more while SBI-100 is still in early clinical testing, when demand is small and switching costs are high. In 2025, Skye reported a net loss and limited operating scale, so vendor concentration can hit costs and timelines fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh switching costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh switching costs raise supplier power for Skye Bioscience, Inc. because changing even 1 CRO, lab, or manufacturing partner can force re-validation, new comparability work, and regulatory re-review. In drug development, those handoffs can push timelines by 3 to 6 months or more, so vendors gain leverage even when Skye Bioscience, Inc. is too small to negotiate hard. That friction makes supplier terms harder to reset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReliance on clinical service providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. depends on investigators, clinical sites, ophthalmic specialists, and trial logistics providers to run Phase I work, so these vendors can slow patient recruitment and weaken data quality if terms are poor. For a small sponsor, that creates moderate supplier power, especially when site capacity is tight and specialist oversight is scarce.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKey vendors control enrollment speed.\u003c\/li\u003e\n\u003cli\u003eSpecialists affect data quality.\u003c\/li\u003e\n\u003cli\u003eSmall sponsor means less pricing power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFunding-constrained purchasing leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience, Inc.'s supplier leverage is capped by its need to conserve cash and move programs fast, so it has less room to push back on pricing and terms. In small biotech, vendors can charge more or demand tighter milestones because larger pharmas can spread spend across bigger pipelines. That keeps supplier power moderate to high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash discipline weakens buying power\u003c\/li\u003e\n\u003cli\u003eSmall scale limits vendor pushback\u003c\/li\u003e\n\u003cli\u003eSupplier power stays moderate to high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Faces Strong Supplier Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience’s supplier power is moderate to high because it depends on a small set of CROs, CMOs, and specialized ophthalmic vendors. In 2025, Skye Bioscience reported a net loss and still had limited operating scale, which weakens its bargaining power on price, timelines, and contract terms. High switching costs and FDA-grade compliance keep vendors in control.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003ePre-revenue\u003c\/td\u003e\n\u003ctd\u003eWeak buyer power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProfitability\u003c\/td\u003e\n\u003ctd\u003eNet loss\u003c\/td\u003e\n\u003ctd\u003eLess room to push back\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVendor mix\u003c\/td\u003e\n\u003ctd\u003eCROs, CMOs, specialists\u003c\/td\u003e\n\u003ctd\u003eHigher supplier leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses competition, supplier and buyer power, new entrants, and substitutes shaping Skye Bioscience, Inc.’s market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly gauge Skye Bioscience’s competitive pressure points with a clear, one-page Five Forces snapshot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Skye Bioscience, Inc. that strengthens credibility and speeds informed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed product customers yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience has no marketed product yet, so end buyers have little bargaining power today because there is nothing to buy or price-shop. The company is still in clinical development, so value creation depends on trial progress, not commercial discounts. That keeps customer influence on revenue terms near zero until approval and launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture payer pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf SBI-100 or SBI-200 wins approval, insurers and pharmacy benefit managers will set the terms, not patients. They can push rebates, narrow coverage, and require proof of both clinical gain and lower total eye-care costs, which raises pricing pressure in ophthalmology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician-driven adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOphthalmologists have strong indirect bargaining power because they drive prescribing and shape treatment guidelines. If Skye Bioscience, Inc. does not show clear efficacy and safety, doctors can stick with established eye therapies, which can slow uptake and limit commercialization.\u003c\/p\u003e\n\u003cp\u003eThis gatekeeper role matters because physician adoption often decides whether a drug reaches broad use, not just whether it is approved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatients have many treatment choices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients have many treatment choices in glaucoma and dry eye, from low-cost generics to SLT, MIGS, punctal plugs, and other device-based options. In the U.S., dry eye affects about 16.4 million adults, and glaucoma is the leading cause of irreversible blindness. If Skye Bioscience, Inc. charges more or adds friction, patients can switch fast, so pricing power stays limited.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMany substitute therapies exist\u003c\/li\u003e\n\u003cli\u003eCost and convenience drive switching\u003c\/li\u003e\n\u003cli\u003eSkye Bioscience, Inc. must stay competitive\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh evidence threshold\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. faces a high evidence bar because biotech buyers want hard proof of benefit, safety, and durability. As a clinical-stage company with 0 approved products and no commercial revenue, Skye must first clear trial data hurdles before it can ask for stronger terms.\u003c\/p\u003e\n\u003cp\u003eThat keeps customer power low to moderate for now, since buyers cannot yet compare a marketed product against established rivals. But once larger Phase 2\/3 data readouts arrive, bargaining power can rise fast if efficacy or safety looks weak.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuyers demand clinical proof.\u003c\/li\u003e\n\u003cli\u003eEarly stage limits pricing power.\u003c\/li\u003e\n\u003cli\u003ePower rises after pivotal data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Faces Weak Customer Bargaining Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. has very low customer bargaining power today because it has no approved products or commercial sales, so there is nothing to price-shop. In clinical stage, buyers judge only trial data, and that keeps leverage limited.\u003c\/p\u003e\n\u003cp\u003eIf SBI-100 or SBI-200 reaches market, insurers and PBMs will set tougher terms, and doctors can still steer use to older, cheaper eye treatments. With dry eye affecting about 16.4 million U.S. adults and glaucoma having many substitutes, pricing power should stay weak.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSkye Bioscience, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Skye Bioscience, Inc. Porter's Five Forces Analysis you'll receive immediately after purchase—no edits, no placeholders, no surprises. The document is fully formatted and ready to use, giving you the same professional analysis you see here. Once you buy, you'll get instant access to this exact file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded glaucoma landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaucoma is a mature market with multiple standard therapies, including prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and combination drops, so pricing and differentiation are tight. Skye Bioscience, Inc. also faces new pipeline entrants from larger biopharma firms, which raises launch risk. The FDA already shows a long list of approved glaucoma drugs, so rivalry is intense from day one.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple ophthalmology developers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. faces heavy rivalry because dry eye, macular degeneration, and diabetic retinopathy each draw many developers and funding rounds. Dry eye alone has had 40+ clinical-stage programs over recent years, and AMD plus diabetic retinopathy continue to attract large biotech and pharma capital, so each indication brings direct and indirect competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-stage differentiation risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSBI-100 is still in Phase I, so Skye Bioscience, Inc. has not yet proven clinical differentiation. In a market where rivals can reach Phase II faster or post stronger efficacy, the \"first-to-market\" and \"best-in-class\" edge is still unclear.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePressure from big pharma and biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience competes in a field where Big Pharma can outspend smaller biotech on trials, licensing, and launch prep. For scale, the top 20 global pharma companies spent over $130 billion on R\u0026amp;D in 2025, giving them deeper clinical muscle and broader pipelines than a small-cap biotech can match. That leaves Skye fighting both fast startups and cash-rich incumbents at once.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig pharma has far more trial cash\u003c\/li\u003e\n\u003cli\u003eBroader pipelines raise competitive pressure\u003c\/li\u003e\n\u003cli\u003eSkye must win on speed and focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and pipeline competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience faces high rivalry because biotech competitors can match CB1 biology with new patents, delivery methods, or cleaner formulations, so speed matters as much as the asset itself. Skye's dependence on nimacimab, still a single lead clinical program, means any rival with stronger efficacy, longer IP, or faster data readout can narrow its moat quickly.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne lead asset raises pipeline risk.\u003c\/li\u003e\n\u003cli\u003ePatents matter as much as trials.\u003c\/li\u003e\n\u003cli\u003eFaster readouts can win share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Faces Fierce Competition in Crowded Eye-Drug Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for Skye Bioscience, Inc. because glaucoma and other eye-disease markets already have many approved drugs and deep pipelines, so new entrants face fast pushback on price and efficacy. Big pharma spent over $130 billion on R\u0026amp;D in 2025, which widens the gap versus a small-cap biotech with one lead asset. SBI-100 is still early stage, so any rival with faster data, stronger IP, or better clinical results can win share quickly.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Big Pharma R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$130B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkye lead assets\u003c\/td\u003e\n\u003ctd\u003e1 core program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket setup\u003c\/td\u003e\n\u003ctd\u003eMany approved rivals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting glaucoma standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExisting glaucoma standards keep substitution risk high for Skye Bioscience, Inc.: patients and physicians already use prostaglandins, beta blockers, carbonic anhydrase inhibitors, and fixed-dose combinations. These therapies are familiar, broadly covered, and anchored by a large market of more than 80 million people with glaucoma worldwide. So a new entrant must beat drugs with decades of prescriber trust and strong access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcedural alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcedural substitutes are a real threat in glaucoma: laser trabeculoplasty can lower intraocular pressure by about 20% to 30%, and surgery can beat drops on adherence because it removes daily dosing. With about 80 million people living with glaucoma worldwide, even small gains in pressure control can shift patients away from drug-based options. That keeps substitute pressure meaningful for Skye Bioscience, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOff-label and generic competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneric drugs still fill about 90% of U.S. prescriptions but take only about 13% of drug spending, so low-cost eye drops and off-label use can win on price. In chronic eye disease, cost and dosing burden strongly shape adherence, which makes cheaper substitutes hard to ignore.\u003c\/p\u003e\n\u003cp\u003eSkye Bioscience, Inc. has to show clear clinical gains, not just a different mechanism, to pull patients and doctors away from entrenched options. If the benefit is modest, generics and off-label therapies remain a strong substitute threat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOther mechanism platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-cannabinoid platforms can still hit the same goals Skye Bioscience, Inc. targets, like inflammation, neuroprotection, tear production, and intraocular pressure, but through different biology. In 2025, several rival programs were already in clinical development across these areas, so a faster readout or better efficacy can quickly make Skye Bioscience, Inc.’s assets less attractive. That makes substitution risk broad, not just tied to one product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame endpoints, different biology\u003c\/li\u003e\n\u003cli\u003eFaster rivals can win adoption\u003c\/li\u003e\n\u003cli\u003eRisk spans the whole pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBehavioral and device-based management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBehavioral and device-based care keeps the substitution risk moderate to high for Skye Bioscience, Inc., because many patients try monitoring, adherence support, and lifestyle changes before starting another drug. In glaucoma, about 3 million Americans have the disease, and treatment delay is common when pressure control is still borderline, so \"watchful waiting\" can act like a practical substitute.\u003c\/p\u003e\n\u003cp\u003eDevice-enabled options, such as home monitoring and sustained-use devices, can also postpone or replace near-term drug uptake, especially when patients want fewer side effects or simpler routines. That makes switching costs low and weakens pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonitoring can delay drug starts\u003c\/li\u003e\n\u003cli\u003eLifestyle changes can reduce urgency\u003c\/li\u003e\n\u003cli\u003eHome devices can replace near-term therapy\u003c\/li\u003e\n\u003cli\u003eDelayed treatment is a real substitute\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Faces Fierce Glaucoma Substitutes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for Skye Bioscience, Inc. because glaucoma care already has cheap generics, laser therapy, and surgery. About 80 million people live with glaucoma worldwide, and roughly 3 million Americans have it, so even small gains in pressure control can pull demand from new drugs. If Skye Bioscience, Inc. does not show clear benefit, substitutes stay dominant.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e90% of U.S. Rx, 13% spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaser\u003c\/td\u003e\n\u003ctd\u003e20% to 30% IOP drop\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma burden\u003c\/td\u003e\n\u003ctd\u003e80M global, 3M U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh regulatory barriers keep new entrants out of ophthalmology. A new drug must pass preclinical work, multiple clinical phases, and FDA review, a path that often takes 8-12 years and can cost over $1 billion. In 2025, that time and capital burden makes easy entry unlikely for Skye Bioscience, Inc.'s niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech entry is capital heavy: a Phase 1-2 program can cost $10M-$30M, and Phase 3 often runs $50M-$100M+. That cash burn makes it hard for new entrants to reach proof of concept without repeated funding rounds. Skye Bioscience, as a clinical-stage developer, benefits because fewer rivals can fund the same path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP and scientific complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatent protection, formulation expertise, and clinical know-how raise Skye Bioscience, Inc.'s entry barriers, because a rival must both invent a molecule and defend it legally. In ocular drug development, even one failed trial can burn years of work; the FDA approved only 55 novel drugs in 2023, underscoring how hard regulated entry is. That makes new entry tough, especially when scientific differentiation matters as much as IP.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eYet biotech startups can still form\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYet biotech startups can still form: in 2025, venture money kept flowing to assets with clear human data, especially in ophthalmology. That means a novel mechanism or strong academic proof can still open the door, even when capital is tight and validation takes time. So the threat of new entrants is not low; it is just filtered hard by funding and science.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNovel science still attracts VC\u003c\/li\u003e\n\u003cli\u003eOphthalmology keeps spawning startups\u003c\/li\u003e\n\u003cli\u003eCapital and proof remain the gate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership pathways reduce barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience operates in a field where new entrants can license programs, outsource preclinical and clinical work, and lean on CROs instead of building full in-house teams. That keeps the upfront capital burden low; in 2025, many biotech startups still launched with lean cash models and shared development capacity. So the threat of new entrants is moderate, not minimal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicense assets instead of inventing from scratch\u003c\/li\u003e\n\u003cli\u003eUse CROs to cut fixed costs\u003c\/li\u003e\n\u003cli\u003ePartnering lowers infrastructure needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Faces Moderate Biotech Entry Barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Skye Bioscience, Inc. is moderate, not low. FDA drug development still takes 8-12 years, and Phase 1-2 can cost $10M-$30M while Phase 3 can reach $50M-$100M+, so capital and time stay the main gate. In 2025, licensing, CRO use, and VC-backed startups still let some new biotech players enter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003e2025 Signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment time\u003c\/td\u003e\n\u003ctd\u003e8-12 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1-2 cost\u003c\/td\u003e\n\u003ctd\u003e$10M-$30M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 cost\u003c\/td\u003e\n\u003ctd\u003e$50M-$100M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA novel drugs approved\u003c\/td\u003e\n\u003ctd\u003e55 in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235018481929,"sku":"skye-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/skye-five-forces.webp?v=1785731704","url":"https:\/\/dcfanalyst.com\/products\/skye-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}